Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.
RNAi (RNA interference) holds great hope for applications involving the “silencing” of genes responsible for particular diseases, resulting in the cure or even prevention of such diseases. This hope is founded on the fact that RNAi is based on an already existing natural cellular process. Because the process already exists within all cells, 
RNAi may be able to be very efficiently introduced into a cell in a therapeutic fashion. Historically, however, there have been significant challenges involved in the delivery of siRNAs (small interfering RNAs).
learn more...
October 6, 2009 - Kylin Therapeutics Receives Notice of Allowance for Key Therapeutic RNA Patent Covering pRNAi Technology
July 17, 2009 - 3 in Purdue Research Park named Companies to Watch
July 16, 2009 - Kylin Therapeutics to expand cancer treatment research with NIH funding- more news...
